ClinicalTrials.gg
CompletedNCT00344175Updated Feb 2, 2010Results posted

Follow-on Protocol of Pitavastatin Versus Simvastatin in Patients With Hypercholesterolemia or Dyslipidemia and Coronary Heart Disease Risk Factors

A Phase 3 interventional study of pitavastatin and simvastatin in Hypercholesterolemia, Dyslipidemia and Coronary Heart Disease, sponsored by Kowa Research Europe. Completed at 28 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2010-02-02.

Sponsored by Kowa Research Europe (part of Kowa Company, Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
178
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 19 studies testing pitavastatin in Hypercholesterolemia — none open to participants now, none under way, none of them phase 3. pitavastatin · Hypercholesterolemia.

Enrollment
13th of 19
178 · median 200
Started
2006
with 2 others
Phase 3
9 of 19
none open now
Registered
8th of 19
by date
Lead sponsor
7 of 19
Kowa Research Europe

Among the 19 studies testing pitavastatin in Hypercholesterolemia, this one is the 13th largest by enrollment, is one of 3 that started in 2006, is one of 9 in phase 3, and was the 8th registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

None of the 19 studies testing pitavastatin in Hypercholesterolemia is open now. The open studies under Hypercholesterolemia, anywhere →

About pitavastatin

pitavastatin: first FDA approval 2009 (LIVALO). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 19 studies testing pitavastatin in Hypercholesterolemia as a file.
02

Study summary

This is a sixteen-week follow-on and 28 week single-blind extension study for patients who participated in study NK-104-304.

Read the detailed description

This is a sixteen-week, double-blind, active controlled, follow-on and 28 week single blind extension study for patients who participated in NK-104-304.

03

Conditions studied

  • Hypercholesterolemia
  • Dyslipidemia
  • Coronary Heart Disease

Keywords

  • hypercholesterolemia
  • dyslipidemia
  • CHD
  • pitavastatin
  • simvastatin
  • 2 or more risk factors for coronary heart disease
  • combined dyslipidemia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Completed NK-104-304 (NCT 00309738)
  • Hypercholesterolemia or combined dyslipidemia
  • 2 or more risk factors for coronary heart disease (CHD)

Exclusion criteria

Exclusion Criteria:

  • Withdrawn or terminated from NK-104-304 (00309738)
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
178 participants (actual)

Study arms

  • Experimental
    Pitavastatin 4 mg

    Pitavastatin 4 mg once daily

    Drug: pitavastatin

  • Active comparator
    Simvastatin 40mg/80mg

    Simvastatin 40 mg or 80 mg once daily

    Drug: simvastatin

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Patients Attaining NCEP LDL-C Target at Week 16

    Number of patients attaining the National Cholesterol Education Program (NCEP) LDL-C target at Week 16. According to NCEP criteria the target LDL-C is 100 mg/dL.

    Time frame: 16 weeks

  2. Number of Patients Attaining NCEP LDL-C Target at Week 44

    Number of patients attaining National Cholesterol Education Program (NCEP) LDL-C target at Week 44. According to NCEP criteria the target LDL-C is 100 mg/dL.

    Time frame: 44 Weeks

Secondary outcomes

  1. Percent Change From Baseline in LDL-C

    Time frame: Baseline to 44 weeks

07

Results

Posted Jan 18, 2010

Participant flow

Patients with primary hypercholesterolemia or combined dyslipidemia, who have satisfied the inclusion/exclusion criteria of the core study, and completed the core study were eligible for this study.

Participant flow — Overall Study
MilestonePitavastatin 4 mgSimvastatin 40mg/80mg
Started12157
Completed10947
Not completed1210

Outcome measures

PrimaryNumber of Patients Attaining NCEP LDL-C Target at Week 16

Number of patients attaining the National Cholesterol Education Program (NCEP) LDL-C target at Week 16. According to NCEP criteria the target LDL-C is 100 mg/dL.

Time frame:
16 weeks
Reported as:
Number · particpants
Number of Patients Attaining NCEP LDL-C Target at Week 16
particpantsPitavastatin 4 mgSimvastatin 40mg/80mg
Number of Patients Attaining NCEP LDL-C Target at Week 169845
PrimaryNumber of Patients Attaining NCEP LDL-C Target at Week 44

Number of patients attaining National Cholesterol Education Program (NCEP) LDL-C target at Week 44. According to NCEP criteria the target LDL-C is 100 mg/dL.

Time frame:
44 Weeks
Reported as:
Number · Participants
Number of Patients Attaining NCEP LDL-C Target at Week 44
ParticipantsPitavastatin 4 mgSimvastatin 40mg/80mg
Number of Patients Attaining NCEP LDL-C Target at Week 449442
SecondaryPercent Change From Baseline in LDL-C
Time frame:
Baseline to 44 weeks
Reported as:
Mean · percent change
Percent Change From Baseline in LDL-C
percent changePitavastatin 4 mgSimvastatin 40mg/80mg
Percent Change From Baseline in LDL-C-41.81 ± 15.130-41.37 ± 16.425

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pitavastatin 4 mg—4/121 (3.3%)57/121 (47.1%)
Simvastatin 40mg/80mg—7/57 (12.3%)38/57 (66.7%)
Most frequent serious events
Showing 10 of 12
Most frequent serious events
EventPitavastatin 4 mgSimvastatin 40mg/80mg
Angina pectorisCardiac disorders0/1211/57
Myocardial infarctionCardiac disorders0/1211/57
GastroenteritisInfections and infestations0/1211/57
Bladder cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1211/57
Global amnesiaNervous system disorders0/1211/57
Transient ischaemic attackNervous system disorders0/1211/57
Urinary bladder polypRenal and urinary disorders0/1211/57
Myocardial ischaemiaCardiac disorders1/1210/57
CataractEye disorders1/1210/57
Non-cardiac chest painGeneral disorders1/1210/57
Most frequent other events
Most frequent other events
EventPitavastatin 4 mgSimvastatin 40mg/80mg
NasopharyngitisInfections and infestations24/12115/57
MyalgiaMusculoskeletal and connective tissue disorders5/1217/57
HeadacheNervous system disorders2/1215/57
Back painMusculoskeletal and connective tissue disorders10/1213/57
ArthralgiaMusculoskeletal and connective tissue disorders3/1214/57
InfluenzaInfections and infestations7/1213/57
OsteoarthritisMusculoskeletal and connective tissue disorders6/1211/57

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Pitavastatin 4 mgSimvastatin 40mg/80mgTotal
<=18 years000
Between 18 and 65 years9844142
>=65 years231336
Age Continuous
Age Continuous(years)Pitavastatin 4 mgSimvastatin 40mg/80mgTotal
Mean60.4 ± 5.8060.8 ± 6.5260.5 ± 6.02
Sex: Female, Male
Sex: Female, Male(Participants)Pitavastatin 4 mgSimvastatin 40mg/80mgTotal
Female391857
Male8239121
08

Study locations

28 sites
  • Y Forskning, Bispebjerg Hospital
    Copenhagen Nv, Denmark
  • Frederiks Hospital, Kardiologisk
    Frederiksberg, Denmark
  • Kolesterollaboratoriet
    Hellerup, Denmark
  • CCBR A/S
    Vejle, Denmark
  • Middellaan 5
    Breda, Netherlands
  • Bomanshof 8
    Eindhoven, Netherlands
  • Damsterdiep 9
    Groningen, Netherlands
  • Doezastraat 1
    Leiden, Netherlands
  • Kamerlingh Onnesstraat 16-18
    Nijmegen, Netherlands
  • Mathenesserlaan 247
    Rotterdam, Netherlands
  • Reigerstraat 30
    Velp, Netherlands
  • Parkdreef 142
    Zoetermeer, Netherlands
  • Hospital Clinico S. Juan de Alicante
    San Juan, Alicante, Spain
  • Hospital Universitario Reina Sofia
    Cordoba, Spain
  • Hospital Ramon y Cajal
    Madrid, 28000, Spain
  • Fundacion Jimenez Diaz
    Madrid, Spain
  • Hospital Clinico San Carlos
    Madrid, Spain
  • Hospital Clinico Universitario de Santiago
    Santiago de Compostela, Spain
  • Angelholms Sjukhus, Medicinkliniken
    Angelhom, Sweden
  • Sahlgrenska University Hospital, Intermedicin
    Gothenburg, Sweden
  • Hjartmottagningen
    Helsingborg, Sweden
  • Lakarcentrum Nyponet
    Karineholm, Sweden
  • Medicinkliniken
    Ludvika, Sweden
  • Huslakaren i Sandviken
    Sandviken, Sweden
  • Narsjukhuset Sandviken, Kardiologlab, Medicin
    Sandviken, Sweden
  • Hjart & Karlcenter
    Sodertalje, Sweden
  • Karolinska Universitetssjukhuset
    Stockholm, Sweden
  • Hjarthuset AB
    Varberg, Sweden
09

References and documents

Publications

  • Eriksson M, Budinski D, Hounslow N. Long-term efficacy of pitavastatin versus simvastatin. Adv Ther. 2011 Sep;28(9):799-810. doi: 10.1007/s12325-011-0057-6. Epub 2011 Aug 25. PubMed 21874537 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2006, a primary completion of Aug 2007 and a completion of Aug 2007. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2010, 2 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 22, 2006
First posted
Jun 26, 2006
Start
Jun 2006
Primary completionActual
Aug 2007
CompletionActual
Aug 2007
Results first posted
Jan 18, 2010
Last update
Feb 2, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 2, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00344175
First posted
Jun 26, 2006
Start date
Jun 2006
Primary completion
Aug 2007
Completion
Aug 2007
Results posted
Jan 18, 2010
Last update
Feb 2, 2010

Study contacts

Dragos Budinski, MD
study director · Kowa Research Europe

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pitavastatin

Start the discussion